RT Journal Article
T1 Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
A1 López-Corral, Lucia
A1 Caballero-Velázquez, Teresa
A1 López-Godino, Oriana
A1 Rosiñol, Laura
A1 Pérez-Vicente, Sabina
A1 Fernandez-Avilés, Francesc
A1 Krsnik, Isabel
A1 Morillo, Daniel
A1 Heras, Inmaculada
A1 Morgades, Mireia
A1 Rifon, Jose J
A1 Sampol, Antonia
A1 Iniesta, Francisca
A1 Ocio, Enrique-María
A1 Martin, Jesús
A1 Rovira, Montserrat
A1 Cabero, Martín
A1 Castilla-Llorente, Cristina
A1 Ribera, Josep-María
A1 Torres-Juan, Marta
A1 Moraleda, Jose María
A1 Martinez, Carmen
A1 Vázquez, Alejandro
A1 Gutierrez, Gonzalo
A1 Caballero, Dolores
A1 San Miguel, Jesús F
A1 Mateos, María-Victoria
A1 Pérez-Simón, Jose Antonio
K1 Allo-HSCT
K1 Allogeneic hematopoietic stem cell transplantation
K1 Immunomodulatory drug
K1 Multiple myeloma
K1 Proteasome inhibitor
AB Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. Because allo-HSCT can modify not only the biology of the disease, but also the immune system and the microenvironment, it can potentially enhance the response to rescue therapies. Information on the efficacy and safety of novel drugs in patients relapsing after allo-HSCT is lacking, however. The objectives of this study were to evaluate the efficacy and toxicity of rescue therapies in patients with MM who relapsed after allo-HSCT, as well as to compare their efficacy before and after allo-HSCT. This retrospective multicenter study included 126 consecutive patients with MM who underwent allo-HSCT between 2000 and 2013 at 8 Spanish centers. All patients engrafted. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 47%, and nonrelapse mortality within the first 100 days post-transplantation was 13%. After a median follow-up of 92 months, overall survival (OS) was 51% at 2 years and 43% at 5 years. The median progression-free survival after allo-HSCT was 7 months, whereas the median OS after relapse was 33 months. Patients relapsing in the first 6 months after transplantation had a dismal prognosis compared with those who relapsed later (median OS, 11 months versus 120 months; P
YR 2019
FD 2019-05-03
LK http://hdl.handle.net/10668/13914
UL http://hdl.handle.net/10668/13914
LA en
DS RISalud
RD Apr 14, 2025